EUCTR2021-002637-42-ESActive, not recruitingPhase 1
An Open-Label, Multicenter, Outpatient Extension Study to Evaluate the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
CB Biopharma SR0 sites300 target enrollmentStarted: October 4, 2021Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 300
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •- Participant must be =12 years of age at the time of signing informed consent (or giving assent, where required)
- •- Participant must have a caregiver =18 years of age at the time of signing the informed consent; the caregiver(s) must be able to recognize and observe the participant
- •- Participants with an established diagnosis of focal or generalized epilepsy or combined focal and generalized epilepsy with a documented history of stereotypical episodes of prolonged seizures that includes at least 1 of the following:
- •a) Generalized seizure episodes starting with a flurry of absence seizures or myoclonic seizures with a minimum total duration of 5 minutes
- •b) Episodes of a focal seizure with a minimum duration of 3 minutes
- •c) Episodes of a focal seizure or myoclonic seizure for at least 90 seconds followed by a generalized/bilateral tonic-clonic seizure with a minimum total duration of 3 minutes
- •- Prior to the Screening Visit, participant completed a study using Staccato alprazolam
- •- Male and female participants:
- •a) A male participant must agree to use contraception during the Treatment Period and for at least 7 days after investigational medicinal product (IMP) administration
- •b) A female participant is eligible to participate if she is not pregnant, not breastfeeding, and:
- •i) Not a woman of childbearing potential (WOCBP)
- •ii) A WOCBP who agrees to follow the contraceptive guidance during the Treatment Period and for at least 30 days after IMP administration
- •- Participant is capable of giving signed informed consent (or giving assent, where required).
- •The informed consent form (ICF) or a specific assent form, where required, will be signed and dated by minors
- •- The participant’s caregiver(s) must be capable of giving signed informed, which includes compliance with the requirements and restrictions listed in the ICF, the protocol, and the individualized participant management plan (iPMP)
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 49
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 236
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 15
Exclusion Criteria
- •- Participant has a history of convulsive status epilepticus in the 8 weeks prior to the Screening Visit
- •- Participant has a history or presence of known nonepileptic seizures which cannot be distinguished from qualifying epileptic seizures
- •- Participant has a clinically significant known airway hypersensitivity (eg, bronchospasm to known allergens, such as pollen, animals, or food) and/or acute respiratory signs/symptoms (eg, shortness of breath, wheezing on lung auscultation)
- •- Participant has a clinically significant chronic pulmonary disorder (eg, asthma, chronic obstructive pulmonary disease, restrictive lung diseases [including idiopathic pulmonary fibrosis]) and/or recent history or presence of hemoptysis or pneumothorax
- •- Participant has a condition for which oral alprazolam is contraindicated (eg, myasthenia gravis, severe respiratory insufficiency, and sleep apnea syndrome)
- •- Participant is taking any drug that is a strong CYP3A4 inhibitor, including azole antifungal agents (ketoconazole and itraconazole) and nefazodone
- •- Participant is taking any opioids (eg, fentanyl, oxycodone, morphine) or sedative hypnotics on a chronic basis
- •- Participant is taking nonselective beta blockers (eg, propranolol, nadolol, and timolol) on a chronic basis
- •- Participant has an FEV1 <80 % of predicted forced expiratory volume in 1 second (FEV1) as measured via spirometry at the Screening Visit
- •- Participant has an oxygen saturation <95 %
Investigators
Similar Trials
Active, not recruiting
Phase 1
A study to test the safety and tolerability of Staccato alprazolam in study participants 12 years of age and older with epilepsyTreatment of stereotypical prolonged seizureMedDRA version: 20.0Level: LLTClassification code 10076333Term: Prolonged seizureSystem Organ Class: 100000004852EUCTR2021-002637-42-ITCB Biopharma SR300
Active, not recruiting
Phase 1
A study to test the safety and tolerability of Staccato alprazolam in study participants 12 years of age and older with epilepsyTreatment of stereotypical prolonged seizureMedDRA version: 20.0Level: LLTClassification code 10076333Term: Prolonged seizureSystem Organ Class: 10029205 - Nervous system disordersEUCTR2021-002637-42-DECB Biopharma SR300
Active, not recruiting
Phase 1
A study to test the safety and tolerability of Staccato alprazolam in study participants 12 years of age and older with epilepsyTreatment of stereotypical prolonged seizureMedDRA version: 20.0Level: LLTClassification code 10076333Term: Prolonged seizureSystem Organ Class: 10029205 - Nervous system disordersEUCTR2021-002637-42-PLCB Biopharma SR300
Recruiting
Phase 3
A study to test the safety and tolerability of Staccato alprazolam in study participants 12 years of age and older with epilepsyEpilepsyJPRN-jRCT2061210061Toyota Yukihiro20
Active, not recruiting
Phase 1
A study to test the safety and tolerability of Staccato alprazolam in study participants 12 years of age and older with epilepsyTreatment of stereotypical prolonged seizureMedDRA version: 20.0Level: LLTClassification code 10076333Term: Prolonged seizureSystem Organ Class: 10029205 - Nervous system disordersEUCTR2021-002637-42-BGCB Biopharma SR300